We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.84%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$372M
AUM Growth
+$4.91M
Cap. Flow
-$21.9M
Cap. Flow %
-5.89%
Top 10 Hldgs %
47.82%
Holding
97
New
8
Increased
10
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$3.96M
2
MDWD icon
MediWound
MDWD
+$2.57M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.16M
4
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.4M
5
KURA icon
Kura Oncology
KURA
+$1.37M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.71M
2
NTUS
Natus Medical Inc
NTUS
+$4.71M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.96M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.65M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
51
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.14M 0.31%
1,100,000
– –
AUTL
52
Autolus Therapeutics
AUTL
$532M
$1.06M 0.29%
496,150
– –
STIM icon
53
Neuronetics
STIM
$157M
$998K 0.27%
313,717
– –
NGM
54
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$980K 0.26%
74,953
-32,700
-30% -$495K
GMDA
55
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$978K 0.26%
+614,896
New +$1.4M
BHVN icon
56
Biohaven
BHVN
$2.17B
$967K 0.26%
+157,096
New +$1.14M
SCYX icon
57
SCYNEXIS
SCYX
$51.6M
$958K 0.26%
49,883
-6,929
-12% -$135K
MREO
58
Mereo BioPharma
MREO
$48.8M
$944K 0.25%
1,096,513
– –
RGLS
59
DELISTED
Regulus Therapeutics
RGLS
$944K 0.25%
555,555
– –
KNTE
60
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$933K 0.25%
78,074
-146,377
-65% -$1.92M
PRDS
61
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$887K 0.24%
479,386
+28,281
+6% +$84.3K
BWAY
62
Brainsway
BWAY
$628M
$794K 0.21%
440,000
+40,000
+10% +$98.2K
GNFT
63
DELISTED
Genfit
GNFT
$686K 0.18%
187,940
– –
LITS
64
Lite Strategy Inc
LITS
$31.6M
$683K 0.18%
88,357
– –
GHRS icon
65
GH Research
GHRS
$2.1B
$612K 0.16%
52,631
-2,369
-4% -$29.9K
MDNA
66
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$548K 0.15%
+660,000
New +$745K
BDTX icon
67
Black Diamond Therapeutics
BDTX
$110M
$530K 0.14%
313,600
– –
NXTC icon
68
NextCure
NXTC
$22.7M
$516K 0.14%
15,641
– –
CMPS
69
Compass Pathways
CMPS
$1.83B
$508K 0.14%
47,390
-27,500
-37% -$412K
PRQR icon
70
ProQR Therapeutics
PRQR
$268M
$483K 0.13%
+649,383
New +$522K
THRX
71
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$475K 0.13%
81,899
– –
STRO icon
72
Sutro Biopharma
STRO
$400M
$451K 0.12%
8,120
-350
-4% -$20.7K
IMA
73
ImageneBio Inc
IMA
$63.9M
$435K 0.12%
+10,210
New +$590K
OTIC
74
DELISTED
Otonomy, Inc.
OTIC
$434K 0.12%
1,470,199
– –
CMPX icon
75
Compass Therapeutics
CMPX
$358M
$429K 0.12%
188,094
-10,000
-5% -$27.7K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, DAFNA Capital Management held 97 positions worth $372M, up 1.3% from $367M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $21.9M in Q3 2022, closing 10 positions and reducing 34 holdings. Its most notable exit was Natus Medical Inc, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in MediWound worth $1.99M.

  • DAFNA Capital Management's largest Q3 2022 buy was MediWound: 204,082 shares worth $1.99M.
  • DAFNA Capital Management added most to Revolution Medicines in Q3 2022, an estimated $3.96M increase.
  • DAFNA Capital Management's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $6.71M.
  • DAFNA Capital Management fully exited Natus Medical Inc in Q3 2022, selling an estimated $4.71M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $372M portfolio in Q3 2022.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q3 2022.
  • DAFNA Capital Management's portfolio value rose 1.3% quarter-over-quarter to $372M.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.